November 2019 - Cytochrome P450 2D6 Inhibitors drug patent information, global generic entry, market access

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma Pharms	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208339-001	Oct 31, 2018	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Mylan	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208446-001	Oct 31, 2018	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Wockhardt Bio Ag	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208380-001	Feb 27, 2019	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Apotex Inc	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208453-001	Oct 31, 2018	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Teva Pharms Usa	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208432-001	Oct 31, 2018	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Amneal Pharms	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208327-001	Jan 7, 2019	AB	RX	No	No	Start Trial	Start Trial				Start Trial
Rising	ABIRATERONE ACETATE	abiraterone acetate	TABLET;ORAL	208371-001	Feb 25, 2019	AB	RX	No	No	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Mechanism of Action: Cytochrome P450 2D6 Inhibitors